ProfileGDS4814 / ILMN_1811234
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 69% 74% 69% 70% 73% 69% 70% 74% 69% 69% 74% 65% 76% 72% 71% 75% 72% 69% 57% 15% 53% 58% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)70.439869
GSM780708Untreated after 4 days (C2_1)89.887674
GSM780709Untreated after 4 days (C3_1)70.326969
GSM780719Untreated after 4 days (C1_2)74.344770
GSM780720Untreated after 4 days (C2_2)88.250673
GSM780721Untreated after 4 days (C3_2)71.424569
GSM780710Trastuzumab treated after 4 days (T1_1)72.029770
GSM780711Trastuzumab treated after 4 days (T2_1)90.983874
GSM780712Trastuzumab treated after 4 days (T3_1)68.590169
GSM780722Trastuzumab treated after 4 days (T1_2)68.845669
GSM780723Trastuzumab treated after 4 days (T2_2)91.167174
GSM780724Trastuzumab treated after 4 days (T3_2)60.376965
GSM780713Pertuzumab treated after 4 days (P1_1)108.19776
GSM780714Pertuzumab treated after 4 days (P2_1)79.668872
GSM780715Pertuzumab treated after 4 days (P3_1)75.742971
GSM780725Pertuzumab treated after 4 days (P1_2)101.8475
GSM780726Pertuzumab treated after 4 days (P2_2)80.126472
GSM780727Pertuzumab treated after 4 days (P3_2)69.710469
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)53.495457
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)42.442415
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)51.567953
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)54.089658
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)58.867264